H
Hiroyuki Mano
Researcher at University of Tokyo
Publications - 308
Citations - 24554
Hiroyuki Mano is an academic researcher from University of Tokyo. The author has contributed to research in topics: Gene & Cancer. The author has an hindex of 66, co-authored 275 publications receiving 22190 citations. Previous affiliations of Hiroyuki Mano include Astellas Pharma & Nagasaki University.
Papers
More filters
Journal ArticleDOI
Autocrine and/or paracrine growth of aggressive ATLL cells caused by HGF and c-Met
Yasuyuki Onimaru,Kunihiro Tsukasaki,K Murata,Yoshitaka Imaizumi,Young Lim Choi,Hiroo Hasegawa,Kazuyuki Sugahara,Yasuo M A Yamada,Tomomi Hayashi,Masahiro Nakashima,Takashi Taguchi,Hiroyuki Mano,Shimeru Kamihira,Masao Tomonaga +13 more
TL;DR: Adult T-cell leukemia/lymphoma (ATLL) is a neoplasia characterized by the massive invasion of various organs by tumor cells and expression of the gene for c-Met, a receptor tyrosine kinase for hepatocyte growth factor (HGF), was specific to the acute type among 41 patients with ATLL by microarray.
Journal ArticleDOI
Constitutive expression of the granulocyte-macrophage colony-stimulating factor gene in human solid tumors
Hiroyuki Mano,Junji Nishida,Kensuke Usuki,Yoshiro Maru,Yukio Kobayashi,Hisamaru Hirai,Tetsuro Okabe,Akio Urabe,Fumimaro Takaku +8 more
TL;DR: This is the first report that demonstrates expression of the GM-CSF gene in solid tumors at the mRNA level, and it is believed that this gene is involved in granulocyte-macrophage colony-stimulating factor-related cancers.
Journal ArticleDOI
DNA micro-array analysis of myelodysplastic syndrome.
TL;DR: DNA micro-array analysis reveals that each stage of MDS has its own ‘molecular signature’, indicating the feasibility of differential diagnosis of M DS based on gene expression profile and demonstrating that the current clinical diagnosis ofMDS results in the misclassification of patients with regard to these molecular signatures.
Journal ArticleDOI
Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti–PD-1 Therapy
Keigo Chida,Akihito Kawazoe,Toshihiro Suzuki,Masahito Kawazu,Toshihide Ueno,Kazumasa Takenouchi,M. Nakamura,Yasutoshi Kuboki,Daisuke Kotani,Takashi Kojima,Hideaki Bando,Saori Mishima,Takeshi Kuwata,Naoya Sakamoto,Jun Watanabe,Hiroyuki Mano,Masafumi Ikeda,Kohei Shitara,Itaru Endo,Tetsuya Nakatsura,Takayuki Yoshino +20 more
TL;DR: Several transcriptomic features, including CMS classification and related genes, were associated with response to PD-1 blockade in MSI-H/dMMR GI tumors, which can help develop predictive biomarkers or combination immunotherapies.
Journal ArticleDOI
Targeting MEF2D-fusion Oncogenic Transcriptional Circuitries in B-cell Precursor Acute Lymphoblastic Leukemia.
Shinobu Tsuzuki,Takahiko Yasuda,Shinya Kojima,Masahito Kawazu,Koshi Akahane,Takeshi Inukai,Masue Imaizumi,Takanobu Morishita,Koichi Miyamura,Toshihide Ueno,Sivasundaram Karnan,Akinobu Ota,Toshinori Hyodo,Hiroyuki Konishi,Masashi Sanada,Hirokazu Nagai,Keizo Horibe,Akihiro Tomita,Kyogo Suzuki,Hideki Muramatsu,Yoshiyuki Takahashi,Yasushi Miyazaki,Itaru Matsumura,Hitoshi Kiyoi,Yoshitaka Hosokawa,Hiroyuki Mano,Fumihiko Hayakawa +26 more
TL;DR: It is revealed that the CRC integrates the pre-B-cell receptor (BCR) and lipid metabolism to maintain itself and govern malignant phenotypes, opening therapeutic avenues to indirectly target fusion-driven leukemia by disrupting its CRC.